Glenna M Gobar1, Philip H Kass. 1. Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis 95616, USA.
Abstract
OBJECTIVE: To quantify incidence of vaccination practices, postvaccinal reactions, and vaccine site-associated sarcomas in cats. DESIGN: Epidemiologic survey. Animals-31,671 cats vaccinated in the United States and Canada by veterinarians with World Wide Web access. PROCEDURE: Veterinarians used secure Web-based survey forms to report data regarding administered vaccines, postvaccinal inflammatory reactions, vaccine site-associated sarcomas, and detailed information and history on each sarcoma. Data were collected from Jan 1, 1998 to Dec 31, 2000, allowing a 1- to 3-year follow-up of vaccinated cats. RESULTS: Participants reported administering 61,747 doses of vaccine to 31,671 cats; postvaccinal inflammatory reactions developed in 73 cats (11.8 reactions/10,000 vaccine doses), and qualifying vaccine site-associated sarcomas developed in 2 cats (0.63 sarcomas/10,000 cats; 0.32 sarcomas/10,000 doses of all vaccines). CONCLUSIONS AND CLINICAL RELEVANCE: These findings indicate that the incidence of vaccine site-associated sarcomas is low and is not increasing. Thoughtful consideration of the relative risks and benefits of specific vaccines remains the best means of reducing the incidence of sarcomas. It is not necessary to remove postvaccinal granulomas unless malignant behavior is apparent or they persist > 4 months.
OBJECTIVE: To quantify incidence of vaccination practices, postvaccinal reactions, and vaccine site-associated sarcomas in cats. DESIGN: Epidemiologic survey. Animals-31,671 cats vaccinated in the United States and Canada by veterinarians with World Wide Web access. PROCEDURE: Veterinarians used secure Web-based survey forms to report data regarding administered vaccines, postvaccinal inflammatory reactions, vaccine site-associated sarcomas, and detailed information and history on each sarcoma. Data were collected from Jan 1, 1998 to Dec 31, 2000, allowing a 1- to 3-year follow-up of vaccinated cats. RESULTS:Participants reported administering 61,747 doses of vaccine to 31,671 cats; postvaccinal inflammatory reactions developed in 73 cats (11.8 reactions/10,000 vaccine doses), and qualifying vaccine site-associated sarcomas developed in 2 cats (0.63 sarcomas/10,000 cats; 0.32 sarcomas/10,000 doses of all vaccines). CONCLUSIONS AND CLINICAL RELEVANCE: These findings indicate that the incidence of vaccine site-associated sarcomas is low and is not increasing. Thoughtful consideration of the relative risks and benefits of specific vaccines remains the best means of reducing the incidence of sarcomas. It is not necessary to remove postvaccinal granulomas unless malignant behavior is apparent or they persist > 4 months.
Authors: Stephen C Shaw; Michael S Kent; Ira K Gordon; Cameron J Collins; Tamara A Greasby; Laurel A Beckett; Genevieve M Hammond; Katherine A Skorupski Journal: J Am Vet Med Assoc Date: 2009-02-01 Impact factor: 1.936